Online inquiry

IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13322MR)

This product GTTS-WQ13322MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TFPI gene. The antibody can be applied in Hemophilia research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001032281.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7035
UniProt ID P10646
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13322MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13265MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ4667MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ6912MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ5873MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ3510MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ12299MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MT203
GTTS-WQ4289MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ10605MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY3300054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW